---
title: A Phase I, open-label, non-randomized study to evaluate the absorption, distribution, metabolism and excretion and pharmacokinetics of DLX313 (minzasolmin) following a single oral dose of [14C]DLX313 in healthy male participants
euct_id: 2023-507959-29-00
phase: Phase 3
status: Completed
sponsor: Novartis Pharma AG
canonical_url: "https://parkinsonspathways.com/trials/eu/2023-507959-29-00"
eu_clinical_trials_register: "https://euclinicaltrials.eu/ctis-public/view/2023-507959-29-00"
ctis_last_updated: "2025-10-27T02:32:37.426869609"
source: EU Clinical Trials Information System (CTIS)
---
# A Phase I, open-label, non-randomized study to evaluate the absorption, distribution, metabolism and excretion and pharmacokinetics of DLX313 (minzasolmin) following a single oral dose of [14C]DLX313 in healthy male participants

**EU CT Number:** [2023-507959-29-00](https://euclinicaltrials.eu/ctis-public/view/2023-507959-29-00)

## Key Facts

- **Phase:** Phase 3
- **Status:** Completed
- **Sponsor:** Novartis Pharma AG
- **Start Date:** 2024-07-17
- **Completion Date:** 2024-08-15
- **Conditions:** Parkinson’s Disease, Parkinson's disease

## Member States

Trial is authorized in 1 member state: Netherlands.

## Sites (1)

- Pharmaceutical Research Associates Group B.V., Groningen, Netherlands

## Eligibility (CTIS)

- **Minimum age:** 18 Years
- **Maximum age:** 64 Years
- **Sex:** MALE

```
Condition: Parkinson’s Disease; Parkinson's disease
Age groups: adults 18-64
Sex: male
```

---

*Canonical: https://parkinsonspathways.com/trials/eu/2023-507959-29-00*  
*HTML version: https://parkinsonspathways.com/trials/eu/2023-507959-29-00*  
*Source data: https://euclinicaltrials.eu/ctis-public/view/2023-507959-29-00*